|Chemical and physical data|
|Molar mass||348.27 g/mol|
|3D model (Jmol)|
CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA). As of 2007 it was in phase II clinical trials for the treatment of depression. In 2013, it was discontinued for both depression and anxiety.
- Fielding R, Mielach F, Free J, Pande A (2007). Pharmacokinetics and oral bioavailability of CX157, a reversible selective MAO-A inhibitor, in primates (PDF). 2007 AAPS Annual Meeting & Exposition. Retrieved 2009-06-14.
- Clinical trial number NCT00739908 at ClinicalTrials.gov
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|